Domino's Pizza, Inc. (DPZ) Stock Price Today
Aura AI Summary
Key Stats
- $10.23BMarket Cap
- 613,578Volume
- Consumer CyclicalSector
- $438.4252W High
- $282.8952W Low
- 106 DaysTypical Hold Time
- $15.19BEnterprise Value
- 2.57%Div Yield
- -Trading Activity
Track Domino's Pizza, Inc. (DPZ) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Domino's Pizza, Inc. has traded between a low of $282.89 and a high of $438.42, highlighting its annual price range. Buy and sell Domino's Pizza, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Domino's Pizza, Inc.
Domino's is a restaurant operator and franchiser with nearly 19,000 global stores across more than 90 international markets at the end of 2021. The firm generates revenue through the sales of pizza, wings, salads, and sandwiches at company-owned stores, royalty and marketing contributions from franchise-operated stores, and its network of 25 domestic (and five Canadian) dough manufacturing and supply chain facilities, which centralize purchasing, preparation, and last-mile delivery for the firm's U.S. and Canadian restaurants. With roughly $17.7 billion in 2021 system sales, Domino's is the largest player in the global pizza market, ahead of Pizza Hut, Papa John's, and Little Caesars.
Most Recent News
Rezolve AI CFO to discuss AI-driven commerce at Maxim Growth Summit 2026
Rezolve AI announced that Arthur Yao, their Group CFO, will participate in the Consumer & Lifestyle Panel at the Maxim Growth Summit 2026 on October 13. The panel will focus on the rise of agentic commerce and its effects on consumer and lifestyle se...

St. Louis Blues to air 10 Thursday games on Gray Media's ABC 32 in 2026-27 season
The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million house...

Obexelimab shows sustained benefits in IgG4-related disease, reducing steroid toxicity and supporting vaccine response.
Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patien...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.